Antiphospholipid syndrome – causes, symptoms, diagnosis, treatment, pathology

What is antiphospholipid syndrome? In antiphospholipid syndrome, individuals produce antiphospholipid antibodies, which attack the phospholipids in the cell membrane of their own cells, or attack proteins that are bound to those phospholipids. So antiphospholipid syndrome, or APS, is an autoimmune disease.

Find more videos at http://osms.it/more.

Study better with Osmosis Prime. Retain more of what you’re learning, gain a deeper understanding of key concepts, and feel more prepared for your courses and exams. Sign up for a free trial at http://osms.it/more.

Subscribe to our Youtube channel at http://osms.it/subscribe.

Get early access to our upcoming video releases, practice questions, giveaways and more when you follow us on social:
Facebook: http://osms.it/facebook
Twitter: http://osms.it/twitter
Instagram: http://osms.it/instagram

Thank you to our Patreon supporters:
Sumant Nanduri
Omar Berrios
Alex Wright
Suzanne Peek
Arfan Azam
Mingli Féng

Osmosis Mission: Empowering the world’s caregivers with the best learning experience possible.

Knowledge Diffusion Inc (DBA Osmosis) does not provide medical advice. Osmosis and the content available on Osmosis’s properties (Osmosis.org, YouTube, and other channels) do not provide a diagnosis or other recommendation for treatment and are not a substitute for the professional judgment of a healthcare professional in diagnosis and treatment of any person or animal. The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed health care provider. Always seek the advice of a physician or other qualified healthcare provider with any questions you have regarding a medical condition.

(Visited 96 times, 1 visits today)

Other Videos You Might Like:

0 0 votes
Article Rating
Subscribe
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments